Halozyme climbs after record Q2 results and higher 2026 outlook

Halozyme Therapeutics (HALO) is up 15.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears to be tied to a classic beat-and-raise earnings reaction. Halozyme posted record second-quarter results, lifted its full-year 2026 guidance, and highlighted continued momentum in royalty growth, new partnership activity, and share repurchases. ([ir.halozyme.com](https://ir.halozyme.com/news/news-details/2026/HALOZYME-REPORTS-RECORD-SECOND-QUARTER-2026-RESULTS-BEATS-ESTIMATES-AND-RAISES-FULL-YEAR-2026-FINANCIAL-GUIDANCE/default.aspx))

Details:

Second-quarter 2026 total revenue rose 48% year over year to $481 million, while royalty revenue increased 50% to $307.7 million, both record levels for the company. ([ir.halozyme.com](https://ir.halozyme.com/news/news-details/2026/HALOZYME-REPORTS-RECORD-SECOND-QUARTER-2026-RESULTS-BEATS-ESTIMATES-AND-RAISES-FULL-YEAR-2026-FINANCIAL-GUIDANCE/default.aspx))

Management raised full-year 2026 guidance, including total revenue to $1.835 billion to $1.910 billion and non-GAAP diluted EPS to $8.65 to $9.00, up from prior targets. ([ir.halozyme.com](https://ir.halozyme.com/news/news-details/2026/HALOZYME-REPORTS-RECORD-SECOND-QUARTER-2026-RESULTS-BEATS-ESTIMATES-AND-RAISES-FULL-YEAR-2026-FINANCIAL-GUIDANCE/default.aspx))

The company said it signed five new ENHANZE and Hypercon collaboration agreements year to date through July, exceeding its full-year goal of three, which may have reinforced investor confidence in longer-term royalty growth. ([ir.halozyme.com](https://ir.halozyme.com/news/news-details/2026/HALOZYME-REPORTS-RECORD-SECOND-QUARTER-2026-RESULTS-BEATS-ESTIMATES-AND-RAISES-FULL-YEAR-2026-FINANCIAL-GUIDANCE/default.aspx))

Halozyme also repurchased about $333 million of stock in the second quarter, including 4.8 million shares at an average price of $69.30, adding another supportive signal on capital returns. ([ir.halozyme.com](https://ir.halozyme.com/news/news-details/2026/HALOZYME-REPORTS-RECORD-SECOND-QUARTER-2026-RESULTS-BEATS-ESTIMATES-AND-RAISES-FULL-YEAR-2026-FINANCIAL-GUIDANCE/default.aspx))

Sources:

Halozyme, SEC ([ir.halozyme.com](https://ir.halozyme.com/news/news-details/2026/HALOZYME-REPORTS-RECORD-SECOND-QUARTER-2026-RESULTS-BEATS-ESTIMATES-AND-RAISES-FULL-YEAR-2026-FINANCIAL-GUIDANCE/default.aspx))

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$HALO Insider Trading Activity

$HALO insiders have traded $HALO stock on the open market 44 times in the past 6 months. Of those trades, 0 have been purchases and 44 have been sales.

Here’s a breakdown of recent trading of $HALO stock by insiders over the last 6 months:

HELEN TORLEY (PRESIDENT AND CEO) has made 0 purchases and 36 sales selling 201,923 shares for an estimated $13,660,648.
CORTNEY CAUDILL (SVP, CHIEF OPERATING OFFICER) has made 0 purchases and 3 sales selling 28,857 shares for an estimated $1,955,159.
MAHESH KRISHNAN sold 7,304 shares for an estimated $547,800
BERNADETTE CONNAUGHTON has made 0 purchases and 4 sales selling 4,875 shares for an estimated $335,396.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$HALO Hedge Fund Activity

We have seen 339 institutional investors add shares of $HALO stock to their portfolio, and 271 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 1,304,358 shares (-40.5%) from their portfolio in Q1 2026, for an estimated $84,300,657
MILLENNIUM MANAGEMENT LLC removed 992,664 shares (-67.8%) from their portfolio in Q1 2026, for an estimated $64,155,874
ASSENAGON ASSET MANAGEMENT S.A. added 976,321 shares (+4578.9%) to their portfolio in Q2 2026, for an estimated $76,416,644
MIZUHO MARKETS AMERICAS LLC removed 930,463 shares (-70.3%) from their portfolio in Q2 2026, for an estimated $72,827,339
TWO SIGMA INVESTMENTS, LP added 867,592 shares (+120.9%) to their portfolio in Q1 2026, for an estimated $56,072,470
MIZUHO MARKETS CAYMAN LP added 834,500 shares (+inf%) to their portfolio in Q2 2026, for an estimated $65,316,315
JANE STREET GROUP, LLC added 667,363 shares (+406.1%) to their portfolio in Q1 2026, for an estimated $43,131,670

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$HALO Congressional Stock Trading

Members of Congress have traded $HALO stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $HALO stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 03/09.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$HALO Price Targets

Multiple analysts have issued price targets for $HALO recently. We have seen 4 analysts offer price targets for $HALO in the last 6 months, with a median target of $91.5.

Here are some recent targets:

Vikram Purohit from Morgan Stanley set a target price of $93.0 on 05/12/2026
Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $95.0 on 04/29/2026
Mohit Bansal from Wells Fargo set a target price of $75.0 on 02/19/2026
Robert Wasserman from Benchmark set a target price of $90.0 on 02/19/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.